Terms: = Bone cancer AND CgA AND Treatment
22 results:
1. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review.
Neuendorff NR; Khan A; Ullrich F; Yates S; Devarakonda S; Lin RJ; von Tresckow B; Cordoba R; Artz A; Rosko AE
J Geriatr Oncol; 2024 Apr; 15(3):101734. PubMed ID: 38430810
[TBL] [Abstract] [Full Text] [Related]
2. Preserving bone in cancers of the elderly: A necessity.
Bertrand N; Bridoux M; Gaxatte C; Abi Rached H; Turpin A; Letarouilly JG; Vieillard MH
Joint Bone Spine; 2023 Jul; 90(4):105549. PubMed ID: 36796583
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period.
Ni J; Zhang X; Wang H; Si X; Xu Y; Zhao J; Chen M; Zhang L; Wang M
Thorac Cancer; 2022 Feb; 13(4):539-548. PubMed ID: 34970848
[TBL] [Abstract] [Full Text] [Related]
4. Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells.
Salzillo A; Ragone A; Spina A; Naviglio S; Sapio L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445291
[TBL] [Abstract] [Full Text] [Related]
5. Patient assessment and feasibility of treatment in older patients with cancer: results from the IN-GHO
Honecker F; Huschens S; Angermund R; Kallischnigg G; Freier W; Friedrich C; Hartung G; Lutz A; Otremba B; Pientka L; Späth-Schwalbe E; Kolb G; Bokemeyer C; Wedding U;
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3183-3194. PubMed ID: 34312732
[TBL] [Abstract] [Full Text] [Related]
6. Neuroendoscopic surgery for neuroendocrine cancer of the skull base.
Qin X; Hong T; Shen X; Liu Q
Neuro Endocrinol Lett; 2021 Jan; 41(6):296-300. PubMed ID: 33714241
[TBL] [Abstract] [Full Text] [Related]
7. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
8. An update on treatment for post-menopausal metastatic breast cancer in elderly patients.
Menjak IB; Jerzak KJ; Desautels DN; Pritchard KI
Expert Opin Pharmacother; 2018 Apr; 19(6):597-609. PubMed ID: 29601247
[TBL] [Abstract] [Full Text] [Related]
9. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.
Deschler B; Ihorst G; Schnitzler S; Bertz H; Finke J
Bone Marrow Transplant; 2018 May; 53(5):565-575. PubMed ID: 29330399
[TBL] [Abstract] [Full Text] [Related]
10. Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.
Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
J Cancer Res Clin Oncol; 2018 Mar; 144(3):571-577. PubMed ID: 29299751
[TBL] [Abstract] [Full Text] [Related]
11. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A; Pouessel D; Ferlay C; Perol D; Beuzeboc P; Gravis G; Joly F; Oudard S; Deplanque G; Zanetta S; Fargeot P; Priou F; Droz JP; Culine S
Ann Oncol; 2011 Nov; 22(11):2476-2481. PubMed ID: 21436186
[TBL] [Abstract] [Full Text] [Related]
13. [Comorbidity oriented oncology - an overview].
Simanek R; Wuensch M; Edlinger R; Hammerl-Ferrari B; Kramer L; Geissler K
Wien Klin Wochenschr; 2010 Apr; 122(7-8):203-18. PubMed ID: 20503019
[TBL] [Abstract] [Full Text] [Related]
14. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
[TBL] [Abstract] [Full Text] [Related]
16. Early breast cancer in the elderly: assessment and management considerations.
Albrand G; Terret C
Drugs Aging; 2008; 25(1):35-45. PubMed ID: 18184027
[TBL] [Abstract] [Full Text] [Related]
17. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer.
Kalkner KM; Acosta S; Thorsson O; Frederiksen H; Nilsson A; Gustavsson B; Elingsbo M; Stridsberg M; Abrahamsson PA
Prostate Cancer Prostatic Dis; 2006; 9(1):92-8. PubMed ID: 16231013
[TBL] [Abstract] [Full Text] [Related]
18. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract] [Full Text] [Related]
19. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract] [Full Text] [Related]
20. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract] [Full Text] [Related]
[Next]
